Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 7, 1998, Pages 883-889

  Gordeev, Mikhail F ^a   Patel, Dinesh V ^a   England, Bruce P ^a   Jonnalagadda, Supriya ^a   Combs, Jesse D ^a   Gordon, Eric M ^a  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; CALCIUM ANTAGONIST; DEXNIGULDIPINE; NIMODIPINE; NITRENDIPINE; TROMBODIPINE;

ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; MEMBRANE BINDING; NONHUMAN; RAT;

ANIMALS; BINDING, COMPETITIVE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CEREBRAL CORTEX; DIHYDROPYRIDINES; DRUG EVALUATION, PRECLINICAL; NITRENDIPINE; RADIOLIGAND ASSAY; RATS;

EID: 0031693885     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)00048-0     Document Type: Article

References (58)

1. For reviews, see for example: (a) Godfraind, T.; Miller, R.; Wibo, M. Pharmacol. Rev. 1986, 38, 321.
2. (b) Janis, R. A.; Silver, P. J.; Triggle, D. J. Advan. Drug Res. 1987, 16, 309.
3. (c) Sausins, A.; Duburs, G. Heterocycles. 1988, 27, 269.
4. (d) Mager, P. P.; Coburn, R. A.; Solo, A. J.; Triggle, D. J.; Rothe, H. Drug Design & Discovery 1992, 8, 273.
5. (e) Mannhold, R.; Jablonka, B.; Voigdt, W.; Schoenafinger, K.; Schraven, E. J. Med. Chem. 1992, 27, 229.
6. (f) Gaudio, A. C.; Korolkovas, A.; Takahata, Y. J. Pharm. Sci. 1994, 83, 1110.
7. (a) Bossert, F.; Vater, W. US Pat. 3,485,847. Dec. 23, 1969.
8. (b) Meyer, V. H.; Bossert, F.; Wehinger, K.; Stoepel, K.; Vater, W. Arzneim.-Forsch./Drug Res. 1981, 31, 407.
9. (c) Meyer, V. H.; Bossert, F.; Vater, W.; Stoepel, K. US Pat. 3,799, 934. Mar. 26, 1974.
10. (d) Galiano, A. Drugs Fut. 1995, 20, 231.
11. (e) Alajarin, R.; Vaquero, J. J.; Alvarez-Builla, J.; Pastor, M.; Sunkel, C; Casa-Juana, M. F. de; Priego, J.; Statkow, P. R.; Sanz-Aparicio, J. Tetrahedron: Asymmetry, 1993, 4, 617.
12. (f) Alajarin, R.; Alvarez-Builla, J.; Vaquero, J. J.; Sunkel, C; Casa-Juana, M. F. de; Statkow, P. R.; Sanz-Aparicio, J.; Fonseka, I. J. Med. Chem. 1995, 38, 830.
13. (g) Sannita, W. A.; Busico, S.; Di Bon, G.; Ferrari, A.; Riela, S. Int. J. Clin. Pharmacol. Res. 1993, 13, 281.
14. (h) Uehar, Y.; Kawabata, Y.; Ohshima, N.; Hirawa, N.; Takada, S.; Numabe, A.; Nagata, T.; Goto, A.; Yagi, S.; Omata, M. J. Cardiovasc. Pharmacol. 1994, 23, 970.
15. (i) Nakagawa, T.; Yamauchi, Y.; Kondo, S; Fuji, M.; Yokoo, N. Jpn. J. Pharmacol. 1994, 64 (Suppl.1), abst. P-260.
16. (j) Boer, R.; Gekeler, V. Drugs Fut. 1995, 20, 499.
17. (k) Ann. Rep. Med. Chem; Bristol, J. A., Ed.; 1992; Vol 27, p 330.
18. (l) Ann. Rep. Med. Chem.; Bristol, J. A., Ed.; 1992; Vol 27, p 322.
19. (m) Schramm, M.; Thomas, G.; Towart, R.; Franckowiak, G. Nature (London) 1983, 303, 535.
20. (n) Sunkel, C. E.; Casa-Juana, M. F. de; Santos, L.; Garcia, A. G.; Artaljero, C. R.; Vilaroya, M.; Gonzalez-Morales, M. A.; Lopez, M. G.; Cillero, J.; Alonso, S.; Priego, J. G. J. Med. Chem. 1992, 35, 2407.
21. (o) Vo, D.; Matowe, W. C.; Ramesh, M.; Iqbal, M.; Wolowyk, M. W.; Howlett, S. E.; Knaus, E. E. J. Med. Chem. 1995, 38, 2851.
22. (p) Klusa, V. Drugs Fut. 1995, 20, 135.
23. (q) Van Der Staay, F. G.; Freund, W. D.; Gebert, I. Behav. Pharmacol. 1994, 5 (Supl. 1), 46.
24. (r) Bretzel, R.G. et al. Am. J. Kidney Dis. 1993, 21, 53.
25. (s) Cooper, K.; Fray, M. J.; Parry, M. J.; J. Med. Chem. 1992, 35, 3115.
26. (t) Drugs Fut. 1992, 17, 465.
27. For reviews on the use of combinatorial technology for drug discovery, see: (a) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gordon, E. M. J. Med. Chem. 1994, 37, 1233.
28. (b) Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P. A.; Gallop, M. A. J. Med. Chem. 1994, 37, 1385.
29. (c) Moos, W. H.; Green, G. D.; Pavia, M. R. In Ann. Rep. Med. Chem. Vol. 28; Bristol, J. A., Ed.; Academic: San Diego, 1993; pp 315-324.
30. (d) Ecker, D. J.; Crooke, S. T. Biotechnology 1995, 13, 351.
31. (e) Terrett, N. K.; Gardner, M.; Gordon, D. W.; Kobylecki, R. J.; Steele, J. Tetrahedron 1995, 51, 8135.
32. For some recent examples, see for example: (e) Virgilio, A. A.; Ellman, J. A. J. Am. Chem. Soc. 1994, 116, 11580.
33. (f) Pei, Y.; Moos, W. H. Tetrahedron Lett. 1994, 35, 5825.
34. (g) Singh, J.; Allen, M. P.; Ator, M. A.; Gainor, J. A.; Whipple, D. A.; Solowiej, J. E.; Treasurywala., A. M.; Morgan, B. A.; Gordon, T. D.; Upson, D. A. J. Med. Chem. 1995, 38, 217.
35. (h) Freier, S. M.; Konings, D. A. M.; Wyatt, J. R.; Ecker, D. J. J. Med. Chem. 1995, 38, 344.
36. (i) Baldwin. J. J.; Burbaum, J. J.; Henderson, I.; Ohlmeyer, M. H. J. J. Am. Chem. Soc. 1995, 117, 5588.
37. (j) Gordeev, M. F.; Patel, D. V.; Wu, J.; Gordon, E. M. Tetrahedron Lett. 1996, 37, 4643.
38. (k) Gordeev, M. F.; Hui, H. C.; Gordon, E. M.; Patel, D. V.; Tetrahedron Lett. 1997, 38, 1729.
39. (l) Gordeev, M. F.; Gordon, E. M.; Patel, D. V. J. Org. Chem. 1997, 62, 8177.
40. (a) Bunin, B. A.; Ellman, J. A. J. Am. Chem. Soc. 1992, 114, 10997.
41. (b) Kurth, M. J.; Randall, L. A. A.; Chen, C.; Melander, C.; Miller, R. B.; McAlister, K.; Reitz, G.; Kang, R.; Nakatsu, T.; Green, C. J. Org. Chem. 1994, 59, 5862.
42. (c) Yu, K.-L.; Deshpande, M. S.; Vyas, D. M. Tetrahedron Lett. 1994, 35, 8919.
43. (d) Backes, B. J.; Ellman, J. A. J. Am. Chem. Soc. 1994, 116, 11171.
44. (e) Patek, M.; Drake, B.; Lebl, M. Tetrahedron Lett. 1994, 35, 9169.
45. (f) Smith, P. W.; Lai, J. Y. Q.; Whittington, A. R.; Cox, B.; Houston, J. G.; Stylli, C. H.; Banks, M. N.; Tiller, P. R. Bioorg. Med. Chem. Lett. 1994, 4, 2821.
46. (g) Kick, E. K.; Ellman, J. A. J. Med Chem. 1995, 38, 1427.
47. (h) Holmes, C. P.; Jones, D. G. J. Org Chem. 1995, 60, 2318.
48. (i) Campbell, D. A.; Bermak, J. C.; Burkoth, T. S.; Patel, D. V. J. Am. Chem. Soc. 1995, 117, 5381.
49. (j) Murphy, M. M.; Schullek, J. R.; Gordon, E. M.; Gallop, M. A. J. Am. Chem. Soc. 1995, 117, 5381.
50. (a) Furka, A.; Sebestyen, F.; Asgedom, M.; Dibo, G. 14th International Congress of Biochemistry, Prague, Czechoslovakia, July 10-15, 1988; W. de Gruyter: Berlin/New York, 1989; vol. 5, p. 47 (abstract).
51. (b) Furka, A.; Sebestyen, F.; Asgedom, M.; Dibo, G. Int. J. Pept. Protein Res. 1991, 37, 487.
52. (c) Sebestyen, F.; Dibo, G.; Kovacs, A.; Furka, A. Bioorg. Med. Chem. Lett. 1993, 3, 413.
53. Gordeev, M. F.; Patel, D. V.; Gordon, E. M. J. Org. Chem. 1996, 61, 924.
54. Bellemann, P.; Schade, A.; Towart, R. Proc. Natl. Acad. Sci. U.S.A. 1983, 80, 2356.
55. 50 values for pools/crude samples deviate from those of pure compounds due to the assay strategy (discussed in b) and variability in chemical yields of the components.
56. Horning, E. C.; Koo, J.; Fish, M. S.; Walker, G. N. Org. Synth.; Wiley: New York, 1963; Collect. Vol. 4, p 408.
57. Ranz, E.; Bossert, F.; Schutz, H. D.; Von Rintelen, H.; Delzenne, G. A.; De Jaeger, A. A. Photographic material comprising a light-sensitive 1,4-dihydropyridine derivative. US Pat. 3,901,710 A Aug. 26, 1975, 9 pp.
58. Bossert, F.; Wehinger, E.; Stoepel, K.; Vater, W.; Kazda, S. Antihypertensive 1,4-dihydropyridine-carboxylic acid aralkyl esters with smooth muscle spasmolytic activity. US Patent 4,044,141 A Aug. 23, 1977, pp. 34.